Confident UTI diagnosis at the point of care — a rapid diagnostic test designed to support responsible antibiotic prescribing by identifying the most common UTI-associated pathogens during the patient visit.
Designed for use alongside clinical judgment and existing standards of care.
Urinary tract infections are among the most common reasons for antibiotic prescribing, yet diagnosis often relies on symptoms alone or laboratory cultures that return results days later. This gap contributes to unnecessary antibiotic use, repeat visits, and increased healthcare costs.
Clinicians need faster, clinically actionable information — without compromising safety.
VeloxDX is designed to deliver molecular-grade confidence at dipstick-level simplicity and cost.
Standard urine cultures require overnight incubation at minimum, delaying targeted treatment and leaving patients in clinical limbo.
Without rapid results, clinicians prescribe broad-spectrum antibiotics upfront. Up to 50% of UTI-related antibiotic prescriptions are innapropriate.
Current point-of-care dipsticks rely on indirect markers like nitrite and leukocyte esterase with well-documented limitations in sensitivity and specificity.
VeloxDX detects agmatine, a metabolic byproduct produced specifically by Enterobacterales, the bacterial family responsible for over 80% of UTIs. Agmatine is a novel urinary biomarker, clinically validated in a peer-reviewed study of 1,629 patient samples. Unlike existing dipstick markers (nitrite, leukocyte esterase), agmatine is produced only by infection-causing bacteria, not by the host immune response or contamination, enabling direct pathogen detection rather than indirect proxy measurement.
VeloxDX uses an electrochemical biosensor on a disposable test strip, paired with a compact handheld reader. No cartridges, no reagent handling, no lab infrastructure. The strip-based format is designed for high-volume, cost-sensitive settings including urgent care clinics, pharmacies, and primary care offices.
The VeloxDX platform is designed with extensibility in mind. While our initial focus is UTI, the underlying technology has potential applications across additional infectious disease indications and care settings, including veterinary medicine.
Rapid, accurate UTI diagnostics have the potential to improve patient outcomes, reduce healthcare costs, and support antimicrobial stewardship efforts across care settings.
Statistics are illustrative and based on published literature. Actual figures may vary by region and population.
VeloxDX is committed to scientific rigor, clinical relevance, and regulatory transparency. We share our progress with the research community as we advance.
Chan, Gregson, Wildman et al. (2025) established agmatine as a clinically validated urinary biomarker for Enterobacterales detection.
View PublicationWe're actively engaging with investors, strategic partners, and clinical collaborators. We look forward to hearing from you and sharing more.
info@veloxdx.com